Page 51 - Read Online
P. 51

Chávez-Castillo et al. Vessel Plus 2018;2:6  I  http://dx.doi.org/10.20517/2574-1209.2018.02                                       Page 9 of 11

               34.  Biswas SK, Mantovani A. Macrophage plasticity and interactionwith lymphocyte subsets: cancer as a paradigm. Nat Immunol
                   2010;11:889-96.
               35.  Ahern GP. 5-HT and the immune system. Curr Opin Pharmacol 2011;11:29-33.
               36.  Kopp S, Alstergren P. Blood serotonin and joint pain in seropositive versus seronegative rheumatoid arthritis. Mediators Inflamm
                   2002;11:211-7.
               37.  Gobin V, Van Steendam K, Denys D, Deforce D. Selective serotonin reuptake inhibitors as a novel class of immunosuppressants. Int
                   Immunopharmacol 2014;20:148-56.
               38.  Tynan R, Weidenhofer J, Hinwood M, Cairns M, Day T, Walker F. A comparative examination of the anti-inflammatory effects of SSRI
                   and SNRI antidepressants on LPS stimulated microglia. Brain Behav Immun 2012;26:469-79.
               39.  St-Onge J, Joanisse D, Simoneau J. The stimulation-induced increase in skeletal muscle glycogen synthase content is impaired in
                   carriers of the glycogen synthase XbaI gene polymorphism. Diabetes 2001;50:195-8.
               40.  Levkovitz Y, Ben-shushan G, Hershkovitz A, Isaac R, Gil-Ad I, Shvartsman D, Ronen D, Weizman A, Zick Y. Antidepressants induce
                   cellular insulin resistance by activation of IRS-1 kinases. Mol Cell Neurosci 2007;36:305-12.
               41.  Goldstein MR, Mascitelli L, Pezzetta F. Is the increase in LDL cholesterol induced by selective serotonin reuptake inhibitor therapy a
                   blessing in disguise? Med Hypotheses 2010;74:955-6.
               42.  Avcikurt AS, Sinan S, Kockar F. Antidepressant and antipsychotic drugs differentially affect PON1 enzyme activity. J Enzyme Inhib
                   Med Chem 2015;30:245-9.
               43.  Al-Asmari AK, Ullah Z, Al Masoudi AS, Ahmad I. Simultaneous administration of fluoxetine and simvastatin ameliorates lipid profile,
                   improves brain level of neurotransmitters, and increases bioavailability of simvastatin. J Exp Pharmacol 2017;9:47-57.
               44.  Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT Jr, Pollock BG, Gaffney A, Narayan M, Finkel MS, McCafferty J,
                   Gergel I. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998;279:287-91.
               45.  Kemp AH, Quintana DS, Gray MA, Felmingham KL, Brown K, Gatt J. Impact of depression and antidepressant treatment on heart rate
                   variability: a review and meta-analysis. Biol Psychiatry 2010;67:1067-74.
               46.  Licht CM, de Geus EJ, Seldenrijk A, van Hout HP, Zitman FG, van Dyck R, Penninx BW. Depression is associated with decreased
                   blood pressure, but antidepressant use increases the risk for hypertension. Hypertension 2009;53:631-8.
               47.  Serebruany V, O’Connor C, Gurbel P. Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery
                   disease. Am J Cardiol 2001;87:1398-400.
               48.  Serebruany VL, Gurbel PA. The relations of major platelet receptor expression during myocardial infarction. Monitoring efficacy of
                   GPIIb/IIIa inhibitors by measuring P-selectin? Thromb Haemost 1999;81:314-6.
               49.  Andrade C, Sandarsh S, Chethan K, Nagesh K. Serotonin reuptake inhibitor antidepressants and abnormal bleeding. J Clin Psychiatry
                   2010;71:1565-75.
               50.  Serebruany V. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? Am J Med 2006;119:113-6.
               51.  Musselman D, Marzec U, Manatunga A, Penna S, Reemsnyder A, Knight BT, Baron A, Hanson SR, Nemeroff CB. Platelet reactivity in
                   depressed patients treated with paroxetine. Arch Gen Psychiatry 2000;57:875-82.
               52.  Tseng Y, Chiang M, Huang T, Su K, Lane H, Lai Y. A selective serotonin reuptake inhibitor, citalopram, inhibits collagen-induced
                   platelet aggregation and activation. Thromb Res 2010;126:517-23.
               53.  Lekakis J, Ikonomidis I, Papoutsi Z, Moutsatsou P, Nikolaou M, Parissis J, Kremastinos DT. Selective serotonin re-uptake inhibitors
                   decrease the cytokine-induced endothelial adhesion molecule expression, the endothelial adhesiveness to monocytes and the circulating
                   levels of vascular adhesion molecules. Int J Cardiol 2010;139:150-8.
               54.  Herr N, Mauler M, Witsch T, Stallmann D, Schmitt S, Mezger J, Bode C, Duerschmied D. Acute fluoxetine treatment induces slow
                   rolling of leukocytes on endothelium in mice. PLoS One 2014;9:e88316.
               55.  Hiles S, Révész D, Lamers F, Giltay E, Penninx B. Bidirectional prospective associations of metabolic syndrome components with
                   depression, anxiety, and antidepressant use. Depress Anxiety 2016;33:754-64.
               56.  Shrivastava A, Johnston M. Weight-gain in psychiatric treatment: risks, implications, and strategies for prevention and management.
                   Mens Sana Monogr 2010;8:53-68.
               57.  Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 2001;3:22-7.
               58.  Raeder M, Bjelland I, Vollset S, Steen V. Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors. J Clin
                   Psychiatry 2006;67:1974-82.
               59.  Serretti A, Mandelli L. Antidepressants and body weight. J Clin Psychiatry 2010;71:1259-72.
               60.  McIntyre RS, Park KY, Law CW, Sultan F, Adams A, Lourenco MT, Lo AK, Soczynska JK, Woldeyohannes H, Alsuwaidan M, Yoon J,
                   Kennedy SH. The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical
                   implications. CNS Drugs 2010;24:741-53.
               61.  Reekie J, Hosking S, Prakash C, Kao K, Juonala M, Sabin M. The effect of antidepressants and antipsychotics on weight gain in
                   children and adolescents. Obes Rev 2015;16:566-80.
               62.  Wagner KD, Ambrosini P, Rynn M, Wohlberg C, Yang R, Greenbaum MS, Childress A, Donnelly C, Deas D; Sertraline Pediatric
                   Depression Study Group. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two
                   randomized controlled trials. JAMA 2003;290:1033-41.
               63.  Croft H, Settle E Jr, Houser T, Batey SR, Donahue RM, Ascher JA. A placebo-controlled comparison of the antidepressant efficacy and
                   effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999;21:643-58.
               64.  de Jonghe F, Ravelli DP, Tuynman-Qua H. A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major
   46   47   48   49   50   51   52   53   54   55   56